IGC-AD1:
Bringing Hope to Alzheimer's Agitation
IGC-AD1 represents a breakthrough approach to treating the challenging symptoms of agitation in Alzheimer's disease, offering potential relief for patients.
For Physicians
Support and educational resources
Learn More →
For Families
Support and educational resources
Learn More →IGC-AD1 is designed to target neuroinflammation, potentially stabilize CB1r function and address neurotransmitter imbalances, all hallmarks associated with agitation in Alzheimer’s Dementia.
Phase 1 and Phase 2 trials are registered on clinicaltrials.gov
A Novel Approach to Alzheimer's Agitation
Agitation affects up to 70% of people with Alzheimer's disease, causing significant distress for patients and overwhelming burden for caregivers.
Current treatment options are limited and often come with concerning side effects, leaving families desperate for better solutions.
Our Breakthrough Solution
IGC-AD1 is an investigational oral liquid formulation specifically designed for Alzheimer's agitation.
Our unique dual-API approach targets multiple neurobiological pathways involved in neuropsychiatric symptoms, potentially offering superior efficacy with improved tolerability compared to existing treatments.
The Science Behind IGC-AD1
Patent-protected through 2041 with FDA IND approval
Modulates neurotransmitter systems controlling behavioral responses
Easy-to-administer oral liquid formulation
No Black Boxes: IGC-AD1 is safe and tolerable at three different dosage levels
Targets neuroinflammation in medial temporal brain regions
From discovery to trials: a path toward treating Alzheimer’s Agitation
Preclinical
Preclinical studies have allowed us to identify the potential of IGC-AD1 to be an AD-modifying drug.
Phase I
The study involved participants with mild to moderate Alzheimer’s disease to evaluate the safety and tolerability of IGC-AD1.
Phase II: CALMA
As millions of Alzheimer’s patients present agitation, our ongoing Phase 2 trial brings hope for a treatment.
Join CALMA Trial
An exciting new clinical trial is evaluating an investigational treatment for agitation in Alzheimer's.
